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Abstract
Background: In humans, sex-determining region-Y (SRY) related high-mobility-group box 4 (SOX4) is linked to
development and tumorigenesis. SOX4 is over-expressed in several cancers and has prognostic significance. This
study evaluated whether SOX4 affects oncogenic behavior and chemoradiotherapy response in head and neck
squamous cell carcinoma (HNSCC) cells, and documented the relationship between its expression and prognosis in
oral squamous cell carcinoma (OSCC).
Methods: We used small interfering RNA in HNSCC cells to evaluate the effect of SOX4 on cell proliferation,
apoptosis, chemoradiation-induced apoptosis, invasion, and migration. SOX4 expression in OSCC tissues was
investigated by immunohistochemistry.
Results: SOX4 knockdown (KO) decreased cell proliferation and induced apoptosis by activating caspases-3 and −7,
and poly-ADP ribose polymerase and suppressing X-linked inhibitor of apoptosis protein in HNSCC cells; it also
enhanced radiation/cisplatin-induced apoptosis; and suppressed tumor cell invasion and migration. Immunostaining
showed SOX4 protein was significantly increased in OSCC tissues compared with adjacent normal mucosa. SOX4
expression was observed in 51.8 % of 85 OSCC tissues, and was significantly correlated with treatment failure
(P = 0.032) and shorter overall survival (P = 0.036) in patients with OSCC.
Conclusions: SOX4 may contribute to oncogenic phenotypes of HNSCC cells by promoting cell survival and
causing chemoradioresistance. It could be a potential prognostic marker for OSCC.
Keywords: SOX4 protein, Radioresistance, Apoptosis, Molecular targeted therapy, Oral cancer, Head and neck
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Background
Oral cavity cancer accounts for approximately 28 % of
all head and neck cancers [1]. Squamous cell carcinomas
represent about 90 % of oral cavity cancer. Oral squa-
mous cell carcinoma (OSCC) is the sixth most prevalent
malignancy worldwide and the third most common can-
cer in developing nations [1]. Surgery, radiation therapy,
chemotherapy or combinations of these modalities are
standard options for managing OSCC; therapeutic
strategies are based on disease stage [2]. As advanced-
stage OSCC has a poor prognosis [1], understanding the
molecular and biological changes of its progression is
critical to development of more effective therapies.
In humans, the sex-determining region Y (SRY) re-
lated high-mobility-group (HMG) box family—also
called the SOX family—includes 20 highly conserved
transcription factors that affect diverse developmental
processes [3]. SOX4 is essential to endocardial develop-
ment and lymphocyte differentiation [3, 4]. Reportedly,
SOX4 expression results in alterations of oncogenic pheno-
types, including inhibition of apoptosis, cell-cycle progres-
sion and irradiation-induced apoptosis, and promotion of
epithelial to mesenchymal transition in a variety of cancer
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cells [5–12]. SOX4 expression has also been reported to be
highly expressed in various cancer tissues [5–14]. How-
ever, its role in tumor progression and clinical outcomes is
unclear and has shown certain contradictions in different
cancers. High SOX4 expression has been associated with
better prognosis for patients with hepatocelluar carcin-
oma, medulloblastoma, and bladder cancer [5, 13, 14], but
with shorter survival in prostate cancer, gastric cancer,
and colon cancer [7, 9, 10]. Thus, SOX4 might exert dif-
ferent effects depending on tumor cell types and context.
Little is known about the molecular and prognostic sig-
nificance of SOX4 in OSCC, although one report corre-
lated SOX4 expression with OSCC tumor stage [12]. In
the present study, we investigated whether SOX4 affects
tumor cell behaviors such as cell proliferation, apoptosis,
invasion, migration, and chemoradiation-induced apop-
tosis in head and neck squamous cell carcinoma (HNSCC)
cells to validate its potential as a novel molecular target.
We also assessed its prognostic value in OSCC.
Methods
Cell culture and transfection
The HNSCC cell lines (PCI 50 and SNU 1041) were kindly
provided by Dr. Sung MW (Seoul National University,
Seoul, South Korea). The normal immortalized human
keratinocyte cell line (HaCaT) was purchased from the
American Type Culture Collection (Manassas, VA, USA).
Cell lines were cultured in DMEM or RPMI1640
(Hyclone, Logan, UT, USA) supplemented with 10 % fetal
bovine serum (Hyclone) in a humidified atmosphere of
5 % CO2 at 37 °C. For transfection, cells were seeded on
6-well plates at 2 × 105 cells per well at the time of trans-
fection. Small interfering RNA (siRNA) was used to knock
down endogenous SOX4 gene expression in HNSCC cells.
Cells were transfected with SOX4-specific siRNA (Bioneer,
Daejeon, Korea) or negative control siRNA (Qiagen,
Valencia, CA, USA) using Lipofectamine™ 2000 (Invitrogen,
Carlsbad, CA, USA) for 48 h. SOX4 knockdown
(SOX4-KO) was checked by reverse transcription-
polymerase chain reaction (RT-PCR) and western blotting.
RNA isolation and RT-PCR
The total RNA from cells was extracted using Trizol re-
agent (Invitrogen), reverse transcribed, and amplified
using specific primers for SOX4 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), as previously de-
scribed [15]. The extracted RNA loading was performed
to verify the RNA integrity and double band (18S and
28S) was detected (Additional file 1). Primer sequences
were: SOX4: 5′-GCA CAT GGC TGA CTA CCCC −3′/
5′-GCC TTGTAC AGC GAG TGG TG-3′; and
GAPDH: 5′-ACC ACA GTC CAT GCC ATC AC-3′/
5′-TCC ACC ACC CTG TTG CTG TA-3′. PCR products
were separated by electrophoresis on a 1 % agarose gel
containing ethidium bromide. The signals were quantified
by densitometric analysis using the Labworks Image
Acquistion (UVP, Upland, CA).
Protein isolation and western blot analysis
Cells were lysed in RIPA buffer. Resolved proteins were
electrophoretically transferred to polyvinylidene fluoride
membranes. Specific proteins were sequentially blotted
with primary antibodies: SOX4 (Catalogue# ab80261,
Abcam, Cambridge, Mass, USA), cleaved caspase-3, cleaved
caspase-7, cleaved poly-ADP ribose polymerase (PARP; Cell
Signaling Technology, Danvers, MA, USA), X-linked in-
hibitor of apoptosis protein (XIAP) and polyclonal anti-
GAPDH (Santa Cruz Biotechnology, CA, USA). Each
membrane was incubated with anti-rabbit or anti-
mouse HRP-conjugated secondary antibody (Santa Cruz
Biotechnology). Immunoreactive proteins were visualized
on the enhanced chemiluminescence detection system
HRP substrate (Millipore, Billerica, MA, USA). The im-
munoreactive bands were quantified by densitometric
analysis using the luminescent image analyzer LAS-4000.
Cell proliferation assay
Cells were seeded in a 96-well plate (5 × 103 cells/well),
and were transfected with SOX4 siRNA and negative
control siRNA the next day. After incubation for 48 h,
cell proliferation and viability were measured using the
EZ-CyTox (tetrazolium salts, WST-1) cell viability assay
kit (Daeil Lab Inc, Seoul, South Korea). After adding
WST-1 reagent for 1–2 h at 37 °C, absorbance at
460 nm was determined using a microplate reader (Infinite
M200; Tecan, Austria GmbH, Austria) with Magellan V6
data analysis software (Tecan). Triplicate wells were used
for experimental conditions and all experiments were re-
peated at least three times.
Apoptosis assay
Apoptosis was determined by an Annexin V-fluorescein
isothiocyanate (FITC) assay. Forty-eight hours after trans-
fection, cells transfected with SOX4 siRNA or negative
control siRNA were collected using trypsin, washed twice
in phosphate buffered saline (PBS), and re-suspended in
binding buffer (BD Biosciences, San Diego, CA, USA).
Annexin V-FITC and 7-amino-actinomycin D (7-AAD;
BD Biosciences) were added to the cells, which were
incubated in the dark for 15 min, then re-suspended in
400 ml of binding buffer. Cells were analyzed using a
FACSCalibur flow cytometer (Becton Dickinson, San Jose,
CA). Data analysis was performed using standard Cell
Quest software (Becton Dickinson).
Cell irradiation and Cisplatin treatment
Cells were treated with γ-irradiation at a single dose of
5 Gy (137Cs, 2.875 Gy/min) using a Gammacell irradiator
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(Gammacell, Otawa, Canada) [16, 17]. Cells were treated
with cisplatin at 10 μg/ml (Pharmachemie BV, New
York, USA) for 24 h at 37 °C.
Cell invasion assay
Cell invasion ability was measured by the number of
cells that invaded through a transwell invasion apparatus
with 8.0-μm pores (Costar, Cambridge, UK). Living cells
transfected with SOX4 siRNA or negative control siRNA
were seeded at 3 × 105 cells in 120 μl of a 0.2 % bovine
serum albumin (BSA) suspension in the upper chamber.
We then loaded 400 μl of 0.2 % BSA containing 7-μg/ml
fibronectin (Calbiochem, La Jolla, CA, USA) into the
lower chamber as the chemoattractant. After incubation
for 24 h, cells that had moved to the bottom Transwell
surface were stained with Diff Quik solution (Sysmex,
Kobe, Japan) and calculated in five random squares in
the microscopic field of view. Results are shown as
mean ± standard error of the number of cells/field in
three individual experiments.
Cell migration assay (wound healing assay)
Cells transfected with SOX4 siRNA or negative control
siRNA were seeded in each well of Culture-Inserts (Ibidi,
Bonn, Germany) at 1.5 × 105 cells/well. After incubation
for 24 h, each insert was detached and the progression
of cell migration was ascertained by photography at 0, 4,
8, 12, and 24 h, using an inverted microscope. Distances
between gaps were normalized to 1 cm after capture of
three random sites.
Fig. 1 Effect of SOX4 knockdown on cell proliferation and apoptosis in head and neck squamous cell carcinoma (HNSCC) cells. a SOX4 protein
and mRNA were well-expressed in HNSCC cells, PCI50 and SNU1041 cells, but not in normal keratinocyte, HaCaT cells. b SOX4 protein and mRNA
expressions were reduced by SOX4 siRNA (SOX4-KO) in PCI50 and SNU 1041 cells compared with negative control siRNA. c Absorbance indicates
that proliferation was decreased in SOX4-KO PCI50 and SNU1041 cells compared with negative control cells (mean ± SE, *P < 0.05; experiments
were run in triplicate). d SOX4-KO PCI50 and SNU1041 cells displayed more apoptosis than in control cells. e Levels of cleaved caspases-3 and −7,
and cleaved poly-ADP ribose polymerase (PARP) were greater, and X-linked inhibitor of apoptosis protein (XIAP) was less, in SOX4-KO PCI50 and
SNU1041 cells than in control cells. C: negative control siRNA transfected cells; S: SOX4-specific siRNA transfected cells (SOX4-KO)
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Patients and tumor specimens
To evaluate SOX4 protein expression, paraffin-embedded
tissue sections were collected from 95 patients who had
undergone diagnostic biopsy or definitive surgery for
OSCC at Chonnam National University Hwasun Hospital
(Jeonnam, Korea) between May 2004 and June 2013. None
of the collected tissues were obtained after radiotherapy
and/or chemotherapy. Ten patients were excluded, because
of follow-up loss or palliative treatment intent. Of the 85
remaining patients, 82 patients were treated with definitive
surgery with/without adjuvant radiotherapy or cisplatin-
based concurrent chemoradiotherapy (CRT). Three pa-
tients, who refused surgery, were treated with induction
chemotherapy, followed by cisplatin-based concurrent CRT
with curative intent. Patients with locoregional recurrence
after primary treatment underwent salvage surgery or CRT.
Of 85 patients in our study, 50 (58.8 %) underwent chemo-
therapy and/or radiotherapy. Treatment failure was defined
as disease with inoperable locoregional progression or dis-
tant metastasis, even through salvage treatment. Patients
provided the written informed consents for the surgical
procedures, as well as for the use of resected tissue
specimens. Patients’ clinicopathologic characteristics were
reviewed in hospital records. Tumors were staged accord-
ing to the seventh edition of the American Joint Committee
on Cancer staging system [18]. Survival was measured from
the date of starting treatment to the date of death or date
last seen. This study was approved by the Institutional
Review Board of Chonnam National University Hwasun
Hospital (CNUHH-2015-028).
Immunohistochemistry
Tissue processing and immunohistochemical analysis
were performed as previously described [15]. The tissues
were incubated with polyclonal rabbit anti-human SOX4
(Abcam). Immunohistochemsitry was performed in five
batches, averaging 18 samples, with one positive and one
negative control per batch. Negative controls were
treated similarly, except that primary antibodies were
omitted.
Two independent observers interpreted SOX4 staining
of specimens with no knowledge of the clinical informa-
tion. Intensity was scored as follows: 0, no staning of
tumor cells; 1+, weak to comparable staining in cyto-
plasm and/or the nucleus compared to that of non-
tumoral cells; 2+, readily appreciable or dark brown
staining distinctly marking the tumor cell cytoplasm
and/or nucleus [10]. Percentages of stained cells were
scored as follows: 0: 0 %; 1: 1–25 %; 2: 26–50 %; 3: 51–
75 %; and 4, >75 % [6, 7]. Final staining scores were the
product of the intensity and percentage scores, with ≤4
defined as low SOX4 expression and >4 defined as high
SOX4 expression. Staining scores were discordant be-
tween the two pathologists (KHL and JHL) in five cases
(5/85, κ = 0.875), which were re-evaluated by the two
pathologists, who then reached an agreement for each
inconclusive sample.
Statistical analyses
Relationships between SOX4 expression and various
clinicopathologic parameters were compared using the
Fig. 2 Effects of SOX4 knockdown (SOX4-KO) on cell invasion and migration in head and neck squamous cell carcinoma cells. a In the cell
invasion assay, significantly fewer SOX4-KO PCI50 and SNU1041 cells invaded than did negative control cells. Stained invading cells were counted
(bar graph; mean ± SE, experiments were run in triplicate; *P < 0.05). b Cell migration was significantly less in SOX4-KO PCI50 and SNU1041 cells
than in negative control cells (displayed as relative healing distances measured in three random sites). Values indicate mean ± SE for three
independent experiments (*P < 0.05). C: negative control siRNA transfected cells; S: SOX4-specific siRNA transfected cells (SOX4-KO)
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Fig. 3 (See legend on next page.)
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χ2 test and Fisher’s exact test. Survival curves were cal-
culated by the Kaplan–Meier method, and compared
using the log-rank test. Experimental differences be-
tween the SOX4-KO group and control group were
tested with the Mann–Whitney U test. Analyses used
Statistical Package for the Social Sciences (SPSS) version
21.0 (Microcal Software Inc, Chicago, IL, USA). P < 0.05
was considered significant.
Results
SOX4-KO suppresses tumorigenic activities in HNSCC cells
Initially, SOX4 expression at mRNA and protein levels
was evaluated in HNSCC cells and HaCaT cells. Western
blot and RT-PCR showed SOX4 to be well-expressed in
PCI50 and SNU1041 cells, but negligibly expressed in
HaCaT cells relative to HNSCC cells (Fig. 1a). To ex-
plore the role of SOX4 on oncogenic activities and treat-
ment response in HNSCC cells, we used siRNA to
inhibit endogenous SOX4 expression in HNSCC cell
lines including PCI50 and SNU1041 cells. SOX4 mRNA
and protein expressions were reduced by SOX4 siRNA
in PCI50 and SNU 1041 cells compared with cells
treated with negative control siRNA (Fig. 1b).
SOX4-KO decreases cell proliferation in HNSCC cells
Proliferating cells, as determined by absorbance, were
significantly decreased in SOX4-KO cells at 48 h and
72 h in PCI50 and SNU1041 cells, as compared with
negative control cells (P = 0.002; Fig. 1c).
SOX4-KO enhances apoptosis in HNSCC cells
To evaulate the effect of SOX4 on apoptosis, we used an
Annexin V apoptosis assay. SOX4-KO PCI50 and
SNU1041 cells displayed greater apoptotic rates than did
control cells (Fig. 1d). The proportion of early and late
apoptotic cells induced by transfection of SOX4 siRNA
was greater than that induced by transfection of negative
control siRNA (9.2 % vs. 33.2 % and 7.1 % vs. 38.1 %, re-
spectively) in PCI50 and SNU1041 cells. Next, we inves-
tigated apoptosis regulatory proteins after SOX4-KO
treatment. Levels of cleaved caspases-3 and −7, and
PARP were increased, and the level of XIAP was de-
creased, in SOX4-KO PCI50 and SNU1041 cells, com-
pared with negative control cells (Fig. 1e). These results
suggest that SOX4-KO-induced apoptosis is associated
with the modulation of apoptosis regulatory proteins
such as caspases-3 and −7, PARP and XIAP.
SOX4-KO suppresses the tumor cell invasion and
migration in HNSCC cells
In the cell invasion assay, the invasiveness of SOX4-KO
PCI50 cells and SNU1041 cells was significantly decreased
(See figure on previous page.)
Fig. 3 Effects of SOX4 knockdown (SOX4-KO) on radiosensitivity and cisplatin chemosensitivity in head and neck squamous cell carcinoma cells.
a, b Combination treatment of SOX4-KO with 5 Gy radiation or cisplatin resulted in significantly more apoptosis in PCI50 and SNU1041 cells than
in control cells treated with 5 Gy radiation or cisplatin treatment alone. c, d SOX4-KO cells showed greater expression of cleaved caspases-3
and −7, and cleaved poly-ADP ribose polymerase (PARP), and less X-linked inhibitor of apoptosis protein (XIAP), than did control cells after 5 Gy
radiation or cisplatin treatment (*P < 0.05). C: negative control siRNA transfected cells; S: SOX4-specific siRNA transfected cells (SOX4-KO); Cis: cisplatin
treatment; IR: irradiation
Table 1 Association between SOX4 expression and
clinicopathological parameters in patients with oral squamous
cell carcinoma
Parameters SOX4 expression p-value
Total (n = 85) Low (n = 41) High (n = 44)
Age (yr) 0.161
<64 41 23 18
≥64 44 18 26
Sex 0.492
Male 61 28 33
Female 24 13 11
Location 0.654
Oral tongue 60 28 32
FOM, BM, RMT 25 13 12
Stage 0.651
I, II 56 28 28
III, IV 29 13 16
T stage 0.843
T1, T2 74 36 38
T3, T4 11 5 6
N stage 0.327
N0 60 31 29
N1, N2 25 10 15
CRT 0.622
No 35 23 27
Yes 50 18 17
Recurrence 0.004
No 53 32 21
Yes 32 9 23
Treatment failure 0.032
No 59 33 26
Yes 26 8 18
FOM = floor of mouth; BM = buccal mucosa; RMT = retromolar trigone; CRT =
chemotherapy and/or radiotherapy; χ2 test and Fisher’s exact test was used
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compared with that of negative control cells (P < 0.05;
Fig. 2a). In the cell migration assay, the migratory ability
of SOX4-KO cells was significantly less than that of nega-
tive control cells at 8 h, 12 h, and 24 h in PCI50 cells, and
8 h and 12 h in SNU1041 cells (P < 0.05; Fig. 2b).
SOX4-KO enhances radiosensitivity and cisplatin
chemosensitivity in HNSCC cells
We addressed whether SOX4-KO enhances cisplatin che-
mosensitivity and radiosensitivity by the induction of apop-
tosis in PCI50 and SNU1041 cells. Twenty-four hours after
transfection with SOX4 siRNA or negative control siRNA,
cells were treated with 5 Gy radiation or cisplatin (10 μg/ml
for 24 h). The combination of SOX4 siRNA and radiation
resulted in significantly greater apoptosis compared with ra-
diation alone (Fig. 3a). The percentages of early and late
apoptotic cells induced by SOX4 siRNA+ 5 Gy radiation
were greater than those seen in negative control cells
treated with 5 Gy radiation (23.1 % vs. 47.7 % and 19.7 % vs.
39.8 %, respectively) in PCI50 and SNU1041 cells. Similarly,
the combination of SOX4 siRNA+ cisplatin resulted in
markedly greater apoptosis compared with cells treated with
cisplatin alone (Fig. 3b), with larger percentages of early and
late apoptotic cells in the SOX4 siRNA+ cisplatin-treated
cells than in the negative control treated with cisplatin only
(18.7 % vs. 51.7 % and 19.0 % vs. 34.4 %, respectively) in
PCI50 and SNU1041 cells. Consistently, the SOX4-KO cells
showed greater expression of cleaved caspases-3 and −7
and PARP, and less XIAP, after radiation or cisplatin treat-
ment compared with the control cells (Fig. 3c, d). These
findings suggest that the combination of SOX4-KO and
CRT has synergistic apoptotic effects in HNSCC cells.
SOX4 expression is associated with treatment failure and
survival in OSCC
SOX4 expression in OSCC tissues
The clinicopathological characteristics of the 85 OSCC
patients in this study group are summarized in Table 1.
The patients included 61 men and 24 women, whose
mean age was 63.2 ± 12.5 years (± standard deviation),
with a range of 26–87 years. Their mean follow-up period
was 43.7 ± 27.7 months (range: 3.6–125.3 months). SOX4
protein expression was investigated immunohistochemi-
cally in formalin-fixed, paraffin-embedded blocks of speci-
mens from these 85 patients. Immunostaining patterns
were heterogenous, with predominantly nuclear and/or
cytoplasmic immunostained SOX4 protein in tumor cells,
but with weak or no staining in the normal oral mucosa
(Fig. 4). Based on our criteria [6, 7, 10], 44 (51.8 %) of the
85 OSCC specimens showed high SOX4 expression.
Correlation between SOX4 expression and clinicopathologic
factors in OSCC tissues
To study the prognostic role of SOX4 in OSCC, we inves-
tigated the correlation between SOX4 expression and clin-
icopathological factors. SOX4 expression in OSCC was
not associated with age, sex, location, T stage (tumor inva-
sion), N stage or lymph node metastasis (P > 0.05, Table 1).
However, SOX4 expression was correlated with recur-
rence (P = 0.004) and treatment failure (P = 0.032; Table 1).
Moreover, overall survival (OS) and diease specific sur-
vival (DSS) of patients with high SOX4 expression was sig-
nificantly shorter than for those with low SOX4
expression (P = 0.036 and P = 0.007, respectively; Fig. 5a).
In 50 patients who were treated with chemotherapy
Fig. 4 Expression of SOX4 protein in oral squamous cell carcinoma (OSCC) specimens. Immunostaining showed SOX4 protein was significantly
increased in OSCC tissues (arrow) compared with adjacent normal mucosa (arrow head). (×100, ×200 in the inlet box)
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and/or radiotherapy, patients with high SOX4 expression
had significantly shorter OS and DSS than those with low
SOX4 expression (P = 0.007 and P = 0.003, respectively;
Fig. 5b).
Discussion
Initiation and progression of cancer are caused by alter-
ations in transcriptional activities, resulting in an imbal-
ance between oncogenes and tumor suppressor genes
[19]. Transcription factors are deregulated in their ex-
pression and function during tumorigenesis [19]. The
SOX transcription factor family plays a key role in many
developmental processes by controlling terminal differ-
entiation of a wide variety of cell types and cell fate deci-
sions [20]. Consequently, deregulation of several SOX
genes have been implicated in tumorigenesis [20]. SOX4
belongs to the C subgroup of the SOX family. High
SOX4 expression has been shown to affect tumor devel-
opment or progression in gastric cancer, colon cancer,
prostate cancer, breast cancer, lung cancer, and endo-
metrial cancer [7–10, 21, 22]. The mechanism by which
SOX4 is involved in tumor development and progression
in many cancers remains unclear.
Tumorigenesis results from an imbalance between cell
proliferation and cell death; most of the latter occurs
through apoptosis [23]. Therefore, the primary mechan-
ism through which SOX4 affects tumor initiation and
progression may be deregulation of apoptosis. SOX4
gene encodes a protein with three distinguishable do-
mains: an HMG box, a serine-rich region, and a glycine-
rich central domain [24]. The HMG box binds DNA,
whereas the central domain is a functional region for
regulating apoptotic cell death [24]. Therefore, we evalu-
ated the impact of SOX4 in cell proliferation and
Fig. 5 Kaplan–Meier curves of overall survival (OS) and disease specific survival (DSS) for patients with oral squamous cell carcinoma (OSCC) by SOX4
expression. a SOX4 expression significantly correlated with diminished OS and DSS in patients with OSCC (n= 85, P= 0.036 and P= 0.007, respectively).
b SOX4 expression was associated with significantly worse OS and DSS in patients with OSCC, who were treated with chemotherapy and/or radiotherapy
(n= 50, P= 0.007 and P= 0.003, respectively). Solid line: patients with low SOX4 expression; dotted line: patients with high SOX4 expression
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apoptosis in HNSCC cells. In this study, knocked-down
SOX4 induced apoptosis and suppressed cell prolifera-
tion, which indicates that SOX4 supresses apoptosis in
HNSCC cells. Additionally, SOX4-KO-induced apoptosis
was associated with the modulation of apoptosis-related
proteins such as caspases-3 and −7, PARP, and XIAP.
Our results concord with reports in which SOX4-KO in
adenoid cystic carcinoma and prostate cancer cells in-
duced apoptosis [6, 7, 25]. Therefore, SOX4 exerts its
anti-apoptotic function by directly inhibiting caspase ac-
tivities and up-regulation of anti-apoptotic proteins, thus
contributing to tumorigenesis in HNSCC.
Second, the anti-apoptotic function of SOX4 apparently
causes resistance to anti-cancer treatement such as CRT.
Cancer cells are often characterized by increased resist-
ance to apoptosis [26]. Overcoming apoptotic resistance is
important to improve response to tumor treatments, es-
pecially CRT. In the present study, knocked-down SOX4
enhanced radiation- or cisplatin-induced apoptosis in
HNSCC cells, which were further supported by elevated
levels of cleaved caspases-3 and −7, and PARP in SOX4-
KO HNSCC cells after radiation or cisplatin treatment.
These results suggest that SOX4 inhibits radiation- or cis-
platin- induced apoptosis, and contributes to CRT resist-
ance in HNSCC cells. These findings are very important
because CRT is used as primary or adjuvant treatment for
locally advanced HNSCC (including OSCC), and CRT
response is accepted as an important prognostic fac-
tor [2, 27]. Our findings suggest that SOX4 can serve as a
specific predictor for CRT response in HNSCC. Further-
more, a therapy in which SOX4 is targeted in combination
with CRT might overcome apoptotic resistance and im-
prove response in HNSCC.
Third, SOX4 appears to aggravate cell invasiveness
and migration. HNSCC subtypes, including OSCC, are
characterized by a marked propensity for local invasion
and lymphatic metastasis. Understanding the molecular
mechanisms that mediate tumor invasion and metastasis
may enable identification of novel therapeutic targets for
management of tumor dissemination. Our study showed
that knocked-down SOX4 suppressed tumor cell inva-
sion and migration in HNSCC cells; earlier studies
showed it to significantly inhibit invasiveness and migra-
tion in prostate cancer cells [7]. These results indicate
that SOX4 contributes to tumor progression and metas-
tasis, and imply that SOX4 could be a useful target in
cancer therapy.
Finally, SOX4 may serve as a biomarker for poor treat-
ment response and outcome in OSCC. In this study, we
found that SOX4 expression was significantly associated
with recurrence, treatment failure and shorter OS. These
results support our results of in vitro study, which associ-
ated SOX4 expression with oncogenic HNSCC phenotypes.
Although several studies have associated SOX4 expression
with shorter survival in prostate cancer, gastric cancer, and
colon cancer [7, 9, 10], this is the first to demonstrate the
correlation between SOX4 expression and treatment failure
in OSCC. More accurate prediction of treatment failure
would facilitate earlier recurrence detection and maximize
the therapeutic effects of salvage treatment. In particular,
among patients with OSCC who received chemotherapy
and/or radiotherapy, those with high SOX4 expression had
significantly shorter OS. These findings indicate that
SOX4-related chemoradioresistance has a pessimistic effect
on survival in patients with OSCC.
Conclusions
Taken together, SOX4 may contribute to invasive and
oncogenic phenotypes of HNSCC cells by promoting cell
survival and causing chemoradioresistance. SOX4 may
be a prognostic marker for OSCC survival outcomes and
treatment response.
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